Today, CardiAI, a leading Biotechnology company specializing in cutting-edge diagnostic solutions, proudly announced a groundbreaking partnership with Carleton University's Faculty of Engineering and Design, marking a significant milestone in advancing medical diagnostics through the implementation of Electrolyte Gated-FET (EG-FET) biosensor technology..

今天，CardiAI，一家专注于尖端诊断解决方案的领先生物技术公司，骄傲地宣布与卡尔顿大学工程与设计学院建立开创性的合作关系，通过实施电解质门控FET（EG-FET）生物传感器技术，标志着在推进医学诊断方面的一个重要里程碑。

Dr. Anmol S. Kapoor and Dr. Ravi Prakash celebrating their groundbreaking partnership. (CNW Group/CardiAI Inc)

Anmol S.Kapoor博士和Ravi Prakash博士庆祝他们开创性的合作关系。（CNW集团/CardiAI Inc）

CardiAI and Carleton are joining forces to harness the potential of EG-FET biosensors for the detection of critical biomarkers in saliva and whole blood. This collaborative effort will not only revolutionize point-of-care diagnostics, but also pave the way for expanding the technology's applications to a broader range of health conditions..

CardiAI和Carleton正在联手利用EG-FET生物传感器的潜力来检测唾液和全血中的关键生物标志物。这种合作不仅将彻底改变即时诊断，而且将为将该技术的应用扩展到更广泛的健康状况铺平道路。

'We are thrilled to embark on this transformative journey with Carleton University,' says Dr. Anmol S. Kapoor, Cardiologist and CEO of CardiAI. 'The marriage of CardiAI's expertise in biotechnology and Carleton's prowess in electronics engineering creates a synergy that holds immense promise for the future of medical diagnostics.

Cardeai首席执行官、心脏病专家安莫尔·卡普尔（AnmolS.Kapoor）博士说，我们很高兴能与卡尔顿大学（CarletonUniversity）一起开始这场变革之旅CardiAI在生物技术方面的专业知识与Carleton在电子工程方面的实力相结合，创造了一种协同作用，为医学诊断的未来带来了巨大的希望。

Together, we are committed to advancing technology that not only addresses current healthcare challenges but also opens new doors for innovation and improved patient outcomes.'.

我们共同致力于推进技术，不仅解决当前的医疗保健挑战，而且为创新和改善患者预后打开新的大门。”

This strategic alliance comes at a crucial time when the global healthcare landscape is evolving, emphasizing the need for accessible and efficient medical testing. The innovative EG-FET biosensor technology is poised to play a pivotal role in democratizing healthcare by providing accurate and rapid diagnostic results, especially for individuals residing in remote areas with limited access to major hospitals.'This collaboration exemplifies the power of interdisciplinary partnerships in driving scientific progress,' says Dr.

这一战略联盟正值全球医疗保健格局不断发展的关键时刻，强调需要进行方便有效的医疗检测。创新的EG-FET生物传感器技术有望通过提供准确快速的诊断结果，在医疗保健民主化方面发挥关键作用，特别是对于居住在偏远地区且无法进入大型医院的个人。”这种合作体现了跨学科伙伴关系在推动科学进步方面的力量。

Ravi Prakash, Associate Professor in Carleton's Department of Electronics and head of Carleton's Organic Sensors and Devices Laboratory. 'Our department is excited to contribute to the development of cutting-edge biosensor technology that has the potential to redefine point-of-care diagnostics. By combining our research strengths, we aim to make a lasting impact on healthcare accessibility and usher in a new era of medical innovation.'Key Highlights of the Partnership:Cutting-Edge Biosensor Technology: The collaboration between CardiAI and Carleton University focuses on the development and implementation of EG-FET biosensor platforms for the detection of NT-proBNP and cardiac troponin biomarkers.

拉维·普拉卡什（RaviPrakash）是卡尔顿电子系副教授、卡尔顿有机传感器和器件实验室负责人我们部门很高兴为尖端生物传感器技术的发展做出贡献，该技术有可能重新定义即时诊断。通过结合我们的研究优势，我们的目标是对医疗保健的可及性产生持久的影响，并开创医疗创新的新时代。”该伙伴关系的关键亮点：尖端生物传感器技术：CardiAI和Carleton大学之间的合作重点是开发和实施EG-FET生物传感器平台，用于检测NT-proBNP和心肌肌钙蛋白生物标志物。

This technology promises to deliver highly sensitive and specific results, enhancing the precision of medical diagnostics. The partnership aims to extend beyond cardiovascular biomarkers, contributing to the development of novel diagnostic solutions for a broader range of health conditions.Global Impact: The collaborative research and development efforts will not only benefit local communities but will also have a global impact.

这项技术有望提供高度敏感和特定的结果，提高医学诊断的准确性。该伙伴关系旨在超越心血管生物标志物，为开发针对更广泛健康状况的新型诊断解决方案做出贡献。全球影响：合作研发工作不仅将使当地社区受益，而且将产生全球影响。

By improving the accessibility of medical tests through point-of-care diagnostics, the partnership strives to make a positive diffe.

通过改进通过即时诊断的医疗测试的可及性，该伙伴关系努力取得积极的差异。

About CardiAI:

关于CardiAI：

CardiAI is a leading biotechnology company dedicated to advancing diagnostic solutions through innovative technologies. With a commitment to precision and efficiency, CardiAI strives to make a positive impact on global healthcare by developing groundbreaking diagnostic tools.

CardiAI是一家领先的生物技术公司，致力于通过创新技术推进诊断解决方案。CardiAI致力于精确和高效，通过开发突破性的诊断工具，努力对全球医疗保健产生积极影响。

About Organic Sensors and Devices Lab (OSDL):

关于有机传感器和器件实验室（OSDL）：

OSDL, a multi-disciplinary research facility at Carleton University, is equipped with advanced manufacturing and direct printing infrastructure and supported by Carleton University Microfab and Nanofab. Our research addresses the growing demand for non-invasive point-of-care diagnostics, rapid and cost-effective chemical and biological sensors, and environmental monitoring systems..

OSDL是卡尔顿大学的一个多学科研究机构，配备了先进的制造和直接印刷基础设施，并得到了卡尔顿大学Microfab和Nanofab的支持。我们的研究满足了对非侵入性即时诊断、快速且经济高效的化学和生物传感器以及环境监测系统日益增长的需求。

About Carleton University:

关于卡尔顿大学：

Carleton is a dynamic, research-intensive institution that engages with industry and government to address the world's most pressing issues. Carleton's Faculty of Engineering and Design is renowned for its commitment to excellence in education and research, pushing the boundaries of technological innovation and developing solutions for a more prosperous and sustainable future.SOURCE CardiAI Inc.

Carleton是一家充满活力的研究密集型机构，与行业和政府合作，解决世界上最紧迫的问题。Carleton的工程与设计学院以致力于卓越的教育和研究而闻名，它推动了技术创新的界限，并为更繁荣和可持续的未来开发了解决方案。SOURCE CardiAI公司。